2023 CAMO ANNUAL SCIENTIFIC MEETING

FINAL PROGRAM

EMERGING NOVEL SYSTEMIC THERAPIES – WHO IS IN CHARGE?

Thursday, April 27, 2023 | MaRS Centre in Toronto, ON

Dr. Stephanie Snow (Halifax, NS)  
2023 ASM Co-Chair

Dr. Zachary Veitch (Barrie, ON)  
2023 ASM Co-Chair

Email: info@camo-acom.ca  
Tel: 613.415.6033  
Website: www.camo-acom.ca
CAMO 2023 ANNUAL SCIENTIFIC MEETING

Overall Objectives

1. Identify ways oncologists can advocate for the Canadian Cancer Care system.
2. Describe various emerging novel systemic therapies in solid tumors.
3. Discuss how novel therapies are implemented into cancer care systems across Canada.
4. Establish and promote a network of medical oncology colleagues from both community and academic settings.

Scientific Planning Committee (SPC)

Co-Chairs
Dr. Stephanie Snow, QEII Health Sciences Centre, Halifax, NS
Dr. Zachary Veitch, Royal Victoria Hospital, Barrie, ON

CPD Representative
Dr. Ghazaleh Kazemi, Juravinski Regional Cancer Centre, Hamilton, ON

Committee Members
Dr. Sharlene Gill, BC Cancer, Vancouver, BC
Dr. Desiree Hao, Tom Baker Cancer Centre, Calgary, AB
Dr. Erin Powell, Dr. H. Bliss Murphy Cancer Centre, St. Johns, NL
Dr. Stephen Welch, London Regional Cancer Program, London, ON

Abstract Judges
Dr. Richard Lee-Ying, Tom Baker Cancer Centre, Calgary, AB
Dr. Jacques Raphael, London Regional Cancer Program, London, ON
Dr. Erica Tsang, Princess Margaret Cancer Centre, Toronto, ON
Dr. Ravi Ramjeesingh, Nova Scotia Cancer Centre, Halifax, NS

Please visit the Virtual Poster Hall that is open to all meeting attendees.

Simply scan the QR Code
CAMO 2023 Annual Scientific Meeting

Thursday, April 27, 2023 | MaRS Centre - Auditorium

07h05 – 07h15 Welcome remarks from CAMO President – Dr. Sharlene Gill

07h15 – 08h15 Sponsored Breakfast Symposium

08h15 – 10h15 CAMO Oral Presentations (12 presentations)

- Objectives (7-minute presentation, followed by 3-minute Q&A)
- At the end of the session, participants will be able to:
  1. Describe recent research findings in the field of Medical Oncology.
  2. Describe interesting cases in the field of Medical Oncology.

- 0815-0825: MAINSTREAM MODEL OF GENETIC TESTING FOR PROSTATE CANCER: THE SUNNYBROOK ODETTE CANCER CENTRE EXPERIENCE | Xin (Kevin) Wang, University of Toronto
- 0825-0835: DOES COMMUNITY SIZE IMPACT SURVIVAL WITH BREAST CANCER? DATA FROM A LARGE POPULATION-BASED COHORT IN BRITISH COLUMBIA | Emily Jackson, University of British Columbia
- 0845-0855: A COMPREHENSIVE FRAMEWORK FOR ASSESSING AND IMPROVING WELLNESS IN THE MEDICAL ONCOLOGY TRAINING PROGRAM AT THE UNIVERSITY OF OTTAWA | Julian Surujballi, University of Ottawa
- 0855-0905: BENEFIT OF ADJUVANT BISPHOSPHONATES IN EARLY BREAST CANCER TREATED WITH CONTEMPORARY SYSTEMIC THERAPY: A META-ANALYSIS OF RANDOMIZED CONTROL TRIALS | Abhenil Mittal, University of Toronto
- 0905-0915: RATES OF SURGERY AND ADJUVANT CHEMOTHERAPY USE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER PATIENTS: AN ONTARIO POPULATION-BASED STUDY | Yuchen Li, McMaster University
- 0915-0925: THE IMPACT OF COVID-19 ON THE WELLNESS AND RESILIENCE OF THE CANADIAN MEDICAL ONCOLOGY WORKFORCE: A CANADIAN ASSOCIATION OF MEDICAL ONCOLOGISTS SURVEY | Lauren Jones, University of British Columbia
- 0925-0935: A RETROSPECTIVE REVIEW OF PRIMARY PROPHYLAXIS WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) FOR PATIENTS WITH GENITOURINARY MALIGNANCIES RECEIVING CHEMOTHERAPY DURING THE COVID-19 PANDEMIC AND IMPLICATIONS FOR THE FUTURE | Nely Diaz Mejia, University of Toronto
- 0935-0945: REAL-WORLD EVALUATION OF BONE TARGETED AGENTS AND FIRST BONE RADIATION INCIDENCE IN PROSTATE CANCER DECEDENTS: A PROVINCIAL-WIDE POPULATION STUDY | William Phillips, University of Ottawa
- 0945-0955: ANEMIA IS INVERSELY ASSOCIATED WITH PATIENT SURVIVAL IN MELANOMA PATIENTS TREATED WITH IMMUNOTHERAPY | Hyejee Ohm, University of Alberta
- 0955-1005: ANDROGEN RECEPTOR IS EXPRESSED IN THE MAJORITY OF BREAST CANCER BRAIN METASTASES AND IS SUBTYPE-DEPENDENT | Kevin Yijun Fan, University of Toronto
- 1005-1015: INFORMATIVE TOOLS TO OPTIMIZE NEOADJUVANT THERAPY IN ER POSITIVE, HER2 NEGATIVE BREAST CANCERS | Lidya Luzhna, University of British Columbia

10h15 – 11h00 Poster Viewing/Judging and Networking Break
CAMO 2023 Annual Scientific Meeting

Thursday, April 27, 2023 | MaRS Centre - Auditorium

11h00 – 12h00 CAMO Keynote Speaker * CLAIM SECTION 3 CREDITS
Physicians as Advocates: What can the Medical Oncologist Community do to Advance Timely and Equitable Cancer Care Access in Canada?
Dr. Paul Wheatley-Price (Ottawa, ON)
Objectives (45-minute presentation followed by 15-minute Q&A)
At the end of the session, participants will be able to:
1. Have a better understanding of the regulatory system in Canada.
2. Have a better understanding of different roles medical oncologists can play in advocating within the system.

12h15 – 13h30 CAMO Annual General Meeting & Lunch (members only) (Room: Auditorium)

12h15 – 13h30 Lunch for Delegates (not attending AGM) (Room: CR-3)

13h45 – 14h00 Sponsor Recognition, Fellowship Presentation & Best Resident Abstracts
Dr. Sharlene Gill – CAMO President
Dr. David Dawe – Chair, Fellowship Committee
Dr. Stephanie Snow & Dr. Zachary Veitch – Co-Chairs, Annual Scientific Meeting Committee

14h00 – 17h00 CAMO Symposium: Emerging Novel Systemic Therapies – Who is in Charge?

14h00 – 14h25 Emerging Adoptive Cell Therapy Strategies in Solid Tumors – Dr. Adrian Sacher (Toronto, ON)
Objectives (25-minute presentation followed by 7-minute Q&A)
At the end of the session, participants will be able to:
1. Review current promising approaches to adoptive cell therapy in solid tumors.
2. Evaluate evolving evidence for promising cell therapy strategies.
3. Discuss potential challenges and toxicities associated with novel cell therapy strategies.

14h32 – 14h57 Bispecifics/BiTE: What a Medical Oncologist Needs to Know – Dr. Maryam Soleimani (Vancouver, BC)
Objectives (25-minute presentation followed by 7-minute Q&A)
At the end of the session, participants will be able to:
1. Discuss what bispecifics and BiTEs are and their mechanism of action.
2. Evaluate potential solid malignancies applicable to these therapies.
3. Evaluate the unique toxicity profile of these drugs and their management.

15h04 – 15h29 Theranostics: Lu-177 PRRT & PSMA-RLT – Dr. Jean-Mathieu Beauregard (Québec City, QC)
Objectives (25-minute presentation followed by 7-minute Q&A)
At the end of the session, participants will be able to:
1. Describe the principles of theranostics.
2. List the indications of PRRT and PSMA-RLT.
3. Appraise their potential benefits and toxicities.

15h40 – 15h50 Poster Viewing and Networking Break

15h50 – 16h50 Panel Discussion
Drs. Mita Manna (Saskatoon, SK) Robyn Macfarlane (Halifax, NS) Adrian Sacher (Toronto, ON)
Maryam Soleimani (Vancouver, BC) Jean-Mathieu Beauregard (Québec City, QC)
Objectives (45-minute discussion followed by 15-minute Q&A)
At the end of the session, participants will be able to:
1. Understand the pan-Canadian perspective on implementing novel therapies
2. Understand their impact to institutional work flows and how they can be successfully integrated for academic or regional/community centers among other insights

16h50 – 17h00 Closing remarks
CAMO 2023 Annual Scientific Meeting

**Thursday, April 27, 2023 | Ontario Heritage Centre**

10 Adelaide Street East, Toronto | *Pre-registration required – no onsite tickets*

18h30-19h00 **CAMO Awards Gala Welcome Reception**

19h00 – 22h00 **Pioneer Lecture Series**

*From Pre-Med to Emeritus Professor: A Personal History (I’m More Surprised Than Anyone To Be Standing Here) – Dr. Peter Venner (Edmonton, AB)*

Objectives (35-minute discussion + 10-minute Q&A)

At the end of the session, participants will be able to:

1. See how easy it is to apply the abilities you have acquired to be a competent medical oncologist (CanMeds in a Nutshell).

**CAMO Annual Achievement Awards presented by**

*Dr. Stephen Welch, Chair Membership Committee & Dr. Sharlene Gill, CAMO President*

**CAMO Pioneer Award Recipient**

Dr. Peter Venner (Edmonton, AB)

**CAMO Rising Star Award Finalists**

Dr. Katarzyna Jerzak (Toronto, ON)
Dr. Aly-Khan Lalani (Hamilton, ON)

**CAMO Distinguished Service Award Finalists**

Dr. Charles Butts (Edmonton, AB)
Dr. Philip Champion (Charlottetown, PEI)
Dr. Scott Ernst (London, ON)
Dr. Natasha Leighl (Toronto, ON)
Dr. Scott North (Edmonton, AB)

**CAMO Volunteer of the Year Award**

To be announced...

---

This event is an Accredited Group Learning Activity *(Section 1)* as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Association of Medical Oncologists. **You may claim a maximum of 5.75 hours** (credits are automatically calculated).

This activity is an Accredited Self-Assessment Program *(Section 3)* as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Association of Medical Oncologists. **You may claim a maximum of 1 hour** (credits are automatically calculated).
THANK YOU!
Please visit the [sponsor showcase](#) to learn more about each company and to connect one-on-one with representatives.

**DIAMOND LEVEL**

Bristol Myers Squibb™

**GOLD LEVEL**

AMGEN®
EMD SERONO
Pfizer

**SILVER LEVEL**

AstraZeneca
Boehringer Ingelheim
Gilead
Kite

**BRONZE LEVEL**

abbvie
Eisai
EMREACH
Ipsen

**BEST RESIDENT ABSTRACT**

Current Oncology